您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2014, Vol. 52 ›› Issue (9): 77-80.doi: 10.6040/j.issn.1671-7554.0.2014.400

• 临床医学 • 上一篇    下一篇

乳腺癌患者血浆D-二聚体水平与预后关系的探讨

李玲1, 王丽丽2, 王胜江2, 于超2, 刘延鹏2, 徐成伟2   

  1. 1. 山东省肿瘤医院外科, 山东 济南 250117;
    2. 山东大学第二医院检验科, 山东 济南 250033
  • 收稿日期:2014-06-16 修回日期:2014-09-04 出版日期:2014-09-10 发布日期:2014-09-10
  • 基金资助:
    济南市高校自主创新计划(201303048)

Research on the relationship between plasma D-dimer level and prognosis of breast cancer

LI Ling1, WANG Lili2, WANG Shengjiang2, YU Chao2, LIU Yanpeng2, XU Chengwei2   

  1. 1. Department of Surgery, Shandong Provincial Tumor Hospital, Jinan 250117, Shandong, China;
    2. Department of Laboratory Medicine, Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Received:2014-06-16 Revised:2014-09-04 Online:2014-09-10 Published:2014-09-10
  • Contact: 徐成伟。E-mail:xuchengwei-jyk@163.com E-mail:xuchengwei-jyk@163.com

PDF (PC)

289

摘要： 目的 分析乳腺癌患者血浆D-二聚体水平的变化，探讨其与乳腺癌患者预后的关系。方法 收集原发性乳腺癌患者92例（病例组）和健康体检者85例（正常对照组），采用胶乳增强免疫比浊法测定血浆中D-二聚体水平，同时采用免疫组化法检测ER、PR、HER2、Ki-67和P53的表达；随访8个月，观察患者生存情况。分析根据不同指标分组的乳腺癌患者血浆D-二聚体水平的变化。结果 病例组与正常对照组相比血浆D-二聚体水平显著升高（P<0.01）；随访期间生存者血浆D-二聚体水平显著低于死亡者（P<0.05）；不同ER、PR、HER2、Ki-67和P53表达的乳腺癌患者间血浆D-二聚体水平无明显差异（P>0.05）。结论 D-二聚体可作为评价乳腺癌预后的指标，能够预测乳腺癌患者生存状况，而与激素受体等免疫组化指标无关。

关键词: 乳腺癌, 预后, 免疫组化, D-二聚体

Abstract: Objective To analyze the changes of plasma D-dimer level in breast cancer patients, and to investigate the relationship between the level of D-dimer and prognosis of breast cancer. Methods A total of 92 cases of primary breast cancer and 85 healthy controls were enrolled. The level of D-dimer was measured with latex-enhanced immunoassay, and ER, PR, HER2, Ki-67 and P53 levels were detected with immunohistochemical methods. During the follow-up of 8 months, the plasma D-dimer levels in breast cancer patients were analyzed. Results The level of D-dimer in breast cancer patients was significantly higher compared to that of the healthy controls (P<0.01); the level of D-dimer in survivors during follow-up was significantly lower than that in those who died (P<0.05); the level of plasma D-dimer in breast cancer patients with different expressions of ER, PR, HER2, Ki-67 and P53 showed no significant difference (P>0.05). Conclusion D-dimer can act as a predictor of breast cancer prognosis, while it has nothing to do with other immunohistochemical indexes.

Key words: Breast cancer, D-dimer, Prognosis, Immunohistochemistry

中图分类号: 

  • R737.9
[1] Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects[J]. Journal of Thrombosis and Haemostasis, 2013, 11(2): 223-233.
[2] Zacharski L R, Ornstein D L. Venous thromboembolism and cancer[J]. N Eng J Med, 2000, 343(5): 1338-47.
[3] Dirix L Y, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer[J]. Br J Cancer, 2002, 86(11): 389-395.
[4] Benoy I H, Salgado R, Elst H, et al. Relative microve-ssel area of the primary tumour, and not lymph node sta-tus, predicts the presence of bone marrow micrometasta-ses detected by reverse transcriptase polymerase chain re-action in patients with clinically non-metastatic breast cancer[J]. Breast Cancer Res, 2005, 7(2): 210-219.
[5] Kono T, Ohtsuki T, Hosomi N, et al. Clinical character-istics of ischemic stroke in elderly patients with cancer[J]. Nihon Ronen Igakai Zasshi, 2011, 48(1): 57-62.
[6] 王丽丽, 徐成伟. 恶性肿瘤血栓形成机制研究进展[J]. 血栓与止血学杂志, 2013, 19(5): 237-240. WANG Lili, XU Chengwei. Advances of Study on Thrombosis in Malignant Tumor[J]. Chinese Journal of Thrombosis and Haemostasis, 2013, 19 (5): 237-240.
[7] 王胜江, 徐成伟. 血浆中凝血酶激活的纤溶抑制物(TAFI)水平与慢性肝损伤相关性研究[J]. 山东大学学报: 医学版, 2012, 50(4): 83-86. WANG Shengjiang, XU Chengwei. Circulating levels of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) in patients with chronic liver disease[J]. Journal of Shan-dong University: Health Sciences, 2012, 50(4): 83-86.
[8] Batschauer A P, Figueiredo C P, Bueno E C, et al. D-di-mer as a possible prognostic marker of operable hormone receptor-negative breast cancer[J]. Ann Oncol, 2010, 21(6): 1267-1272.
[9] Ay C I, Dunkler D, Pirker R, et al. High D-dimer levels are associated with poor prognosis in cancer patients[J]. Haematologica, 2012, 97(8): 1158-1164.
[10] Carey L A, Dees E C, Sawyer L, et al. The triple nega-tive paradox: primary tumor chemosensitivity of breast cancer sub-types[J]. Clin Cancer Res, 2007,13 (8): 2329-2334.
[11] Dent R, Trudeau M, Pritchard K I, et al. Triple-nega-tive breast cancer: clinical features and patterns of recur-rence[J].Clin Cancer Res, 2007, 13(15): 4449-4434.
[12] Kausch I, Lingnau A, Endl E et al. Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo[J]. Int J Cancer, 2003, 105(12): 710-716.
[13] Rosa F E, Cladeira J R, Felipes J, et al. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic fac-tors and proliferative marker Ki-67 in breast cancers[J]. Hum Pathol, 2008, 39(5): 720-730.
[14] Versteeg H H, Schaffner F, Kerver M, et al. Inhibition of tissue factor signaling suppresses tumor growth[J]. Blood, 2008, 111(1): 190-199.
[15] Warnberg F, Nordgren H, Bergkvist L, et al. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness[J]. Br J Cancer, 2001, 85(6): 869-874.
[16] Choi H K, Roh S H, Kim H G, et al. Enhanced expression of aromatase in p53-inactivated mammary epithelial cells[J]. Endocr Relat Cancer, 2008, 15(1): 139-147.
[17] Dent R, Trudeau M, Pritchard K I, et al. Prognostic markers in Triple-negative breast cancer[J]. Cancer, 2007, 109(1): 25-32.
[1] 栗英林,宋道庆,徐忠华. 应用生物信息学方法分析肾透明细胞癌中FKBP11的表达[J]. 山东大学学报 (医学版), 2020, 1(9): 45-51.
[2] 史爽,李娟,米琦,王允山,杜鲁涛,王传新. 胃癌miRNAs预后风险评分模型的构建与应用[J]. 山东大学学报 (医学版), 2020, 1(7): 47-52.
[3] 路璐,孙志钢,张楠. 继发性嗜血细胞综合征1例[J]. 山东大学学报 (医学版), 2020, 1(7): 122-124.
[4] 李星凯,刘战业,姜运峰,李军. 原发性中央型和周围型肺鳞癌临床病理学及预后差异[J]. 山东大学学报（医学版）, 2017, 55(9): 73-78.
[5] 宗帅,肖东杰,刘华,郏雁飞,马晓丽,李焕杰,黎娉,郑燕,汪运山. CSN5在胃癌中的表达及与患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(7): 12-16.
[6] 李雁翔,张温花,杨飞龙,方量,徐忠华. 尿路上皮癌BRCA1基因与蛋白表达的相关性[J]. 山东大学学报（医学版）, 2017, 55(5): 91-94.
[7] 廉开礼,李炎,张娜,靳桂媛,刘素侠. TIPE3上调P-gp表达降低乳腺癌细胞对阿霉素的敏感性[J]. 山东大学学报（医学版）, 2017, 55(5): 36-42.
[8] 孙启晶,陈方方,李春晓,张才擎. PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值[J]. 山东大学学报（医学版）, 2017, 55(4): 55-59.
[9] 董尧,宋亚林,田涛,高建国. 确诊8年未经治疗却无明显进展的阴茎恶性黑色素瘤1例报道[J]. 山东大学学报（医学版）, 2017, 55(3): 125-126.
[10] 林家香,郭子嘉,苏鹏,王晓,郭雅欣,吴晓娟,相磊,周志强, 王妍,崔秀杰,潘爱凤,郭成浩. 致癌蛋白CIP2A在乳腺导管上皮恶变中的作用及预测浸润性导管癌患者预后的能力[J]. 山东大学学报（医学版）, 2017, 55(3): 100-106.
[11] 周兰兰,潘学谊,郭煜. 48例急性混合细胞表型白血病患者的临床特征及预后[J]. 山东大学学报（医学版）, 2017, 55(2): 79-83.
[12] 张希英,翟春颜,李劲松,韩博. 中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系[J]. 山东大学学报（医学版）, 2017, 55(2): 84-91.
[13] 刘惠苓,王兴文,冯少滨,冯虹,韩俊庆. B类I型清道夫受体的高表达与结肠癌患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(10): 84-89.
[14] 李晓宁,崔连群. 急性心肌梗死合并多支血管病变患者非梗死相关动脉处理的时机[J]. 山东大学学报（医学版）, 2016, 54(8): 50-54.
[15] 王雯,刘尧,龙飞,马卫霞,苏莉莉. 外周血淋巴细胞/单核细胞比值与恶性胸膜间皮瘤患者预后的关系[J]. 山东大学学报（医学版）, 2016, 54(8): 72-77.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发